| scholarly article | Q13442814 |
| P50 | author | Nizar N Jarjour | Q88330675 |
| Michael E Wechsler | Q89490244 | ||
| Rayan Khaddaj Mallat | Q91961598 | ||
| Elliot Israel | Q124853372 | ||
| Jun Yang | Q55979568 | ||
| P2093 | author name string | Richard Martin | |
| Bruce D Hammock | |||
| Bruce D Levy | |||
| Mario Castro | |||
| Shamsah Kazani | |||
| E Rand Sutherland | |||
| Emiko Ono | |||
| Marco Sirois | |||
| Eric Rousseau | |||
| National Heart, Lung, and Blood Institute's Asthma Clinical Research Network | |||
| David Nobuhiro Douda | |||
| Chantal Sirois | |||
| Edmond Rizcallah | |||
| Stefanie Dutile | |||
| Yacine Tabet | |||
| P2860 | cites work | Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes | Q24633568 |
| Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses | Q24685948 | ||
| Resolution of inflammation in asthma | Q26823724 | ||
| Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases | Q68462726 | ||
| Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress | Q73251094 | ||
| Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus | Q83185590 | ||
| The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses | Q27693180 | ||
| Asthma | Q28237297 | ||
| Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation | Q28393303 | ||
| Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor | Q28571602 | ||
| Leukotrienes and lipoxins: structures, biosynthesis, and biological effects | Q29617543 | ||
| Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program | Q30422401 | ||
| Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program | Q30433207 | ||
| Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma | Q30438572 | ||
| Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation | Q30442280 | ||
| Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury | Q33386526 | ||
| Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema | Q34290400 | ||
| Measurement of soluble epoxide hydrolase (sEH) activity | Q34436333 | ||
| Epoxyeicosatrienoic acid relaxing effects involve Ca2+-activated K+ channel activation and CPI-17 dephosphorylation in human bronchi. | Q34604156 | ||
| The role of platelets in the pathophysiology of asthma. | Q34656136 | ||
| Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. | Q35679301 | ||
| Corticosteroid resistance in airway disease | Q36236900 | ||
| Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils | Q36353858 | ||
| Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. | Q36438199 | ||
| Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo | Q36445448 | ||
| Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways | Q36647303 | ||
| Förster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase | Q36784547 | ||
| Exhaled breath condensate eicosanoid levels associate with asthma and its severity | Q37138368 | ||
| Diminished lipoxin biosynthesis in severe asthma | Q37282577 | ||
| Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation | Q37445402 | ||
| Asthma phenotypes: the evolution from clinical to molecular approaches | Q38007831 | ||
| EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. | Q38298269 | ||
| Exhaled breath condensate: methodological recommendations and unresolved questions. | Q40392502 | ||
| 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. | Q41486228 | ||
| 17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase | Q43222936 | ||
| Structural refinement of inhibitors of urea-based soluble epoxide hydrolases | Q43990736 | ||
| Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). | Q44097824 | ||
| Platelets are essential for leukocyte recruitment in allergic inflammation. | Q44504339 | ||
| Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. | Q45173567 | ||
| Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound | Q45215082 | ||
| Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma. | Q51057996 | ||
| The effects of lipoxin A4 on airway responses in asthmatic subjects | Q68139797 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| Soluble epoxide hydrolase | Q7558943 | ||
| P304 | page(s) | 886-897 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma | |
| P478 | volume | 190 |
| Q46301404 | A composite of exhaled LTB4 , LXA4 , FeNO, and FEV1 as an "asthma classification ratio" characterizes childhood asthma. |
| Q41068189 | ALX receptor ligands define a biochemical endotype for severe asthma |
| Q60937319 | Biomarkers in asthma: state of the art |
| Q90564702 | Biosynthetic metabolomes of cysteinyl-containing immunoresolvents |
| Q39271007 | Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation |
| Q99201955 | Carcinogenesis: Failure of resolution of inflammation? |
| Q88755027 | Early Intravascular Events Are Associated with Development of Acute Respiratory Distress Syndrome. A Substudy of the LIPS-A Clinical Trial |
| Q97516578 | Eicosanoids: the Overlooked Storm in COVID-19? |
| Q40046428 | Eosinophilic and Non-Eosinophilic Asthma. |
| Q64869053 | Fatty acid chemical mediator provides insights into the pathology and treatment of Parkinson's disease |
| Q93187266 | Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders |
| Q51690602 | Lipoxins and epoxyeicosatrienoic acids. Potential for inhibitors of soluble epoxide hydrolase in severe asthma? |
| Q26784376 | Lipoxins: nature's way to resolve inflammation |
| Q50175494 | Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target. |
| Q28270421 | Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor |
| Q36217771 | Pro-Resolving Effects of Resolvin D2 in LTD4 and TNF-α Pre-Treated Human Bronchi |
| Q37577177 | Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators |
| Q59796123 | Soluble epoxide hydrolase derived lipid mediators are elevated in bronchoalveolar lavage fluid from patients with sarcoidosis: a cross-sectional study |
| Q88540273 | Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases |
| Q28271331 | Specialized pro-resolving mediators: endogenous regulators of infection and inflammation |
| Q38547604 | Update in Asthma 2014. |
| Q92604958 | ZDHXB-101 (3',5-Diallyl-2, 4'-dihydroxy-[1,1'-biphen-yl]-3,5'-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activat |
Search more.